로딩 중...
52주 최고가 대비 94.3% 위치
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $2.89B | $2.95B | $2.89B | $3.07B |
| 영업이익 | - | $760.8M | $707.4M | $590.9M | $636.1M |
| 당기순이익 | - | $585.9M | $593.4M | $492.7M | $493.7M |
| 잉여현금흐름 (FCF) | - | $439.4M | $414.5M | $276.4M | $468.9M |
| 수익성 비율 | |||||
| 영업이익률 | - | 26.4% | 24.0% | 20.4% | 20.7% |
| 순이익률 | - | 20.3% | 20.1% | 17.0% | 16.1% |
| ROE (자기자본이익률) | - | 21.8% | 20.6% | 18.4% | 15.5% |
| ROA (자산이익률) | - | 16.2% | 15.5% | 13.5% | 11.6% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 2.2% | -1.9% | 6.3% |
| EPS 성장률 (YoY) | - | - | 1.9% | -15.1% | 1.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 34.0x | 47.0x | 50.8x | 34.0x |
| PBR (주가순자산배수) | - | 6.9x | 9.1x | 9.0x | 5.1x |
| PSR (주가매출배수) | - | 6.4x | 8.9x | 8.3x | 5.3x |
| FCF Yield | - | 2.4% | 1.6% | 1.2% | 2.9% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.12 | 0.11 | 0.11 | 0.10 |
| 유동비율 | - | 3.70 | 2.88 | 2.79 | 3.02 |
MOLINA HEALTHCARE INC
$179.86
$9.4B